Taiwan Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others) - Forecasts From 2025 To 2030

Taiwan Pain Management Drugs Market Size:

Taiwan pain management drugs market is anticipated to grow at a CAGR of XX% from 2025 to 2030.

Taiwan is emphasizing improving its generic drug production to meet the varied healthcare needs of customers. The country is also witnessing constant growth in its population which is expected to increase the prevalence of various infectious and chronic diseases, especially among older people that will account for a considerable share of the country’s population in the coming years. 

According to the Ministry of Interiors, at the end of December 2024, the total number of populations aged 65 years and above reached 4,488,707 and constituted 19.18% of the total population. Furthermore, as per the same source, the percentage share of the old age population is witnessed to show constant growth and will account for 24.2% of the total population by 2030 and 31% by 2040. With such high growth in figures of the old-age population, the demand for effective medication that assists them in daily activities will also grow thereby providing various growth opportunities for the pain management drugs in the country.

Likewise, other chronic issues such as diabetes which impact the overall health have also become a major concern for people in Taiwan. According to the International Diabetes Federation, in 2024, the prevalence rate of diabetes in the adult population which reached 19 million stood at 10.7% and the number of cases reaching up to 2.59 million.

Additionally, the high cancer, cardiac disease, and gastro-intestinal prevalence has also increased the overall level of medical surgeries in Taiwan which has established a framework bolstering the demand for pain management drugs for post-operative pain. According to the Ministry of Health and Welfare, in 2023, there were 880,000 cancer patients in Taiwan and the average growth rate of cancer drugs between 2014 to 2023 was 9.3%

Moreover, due to the lack of proper lifestyle adoption among people various health issues inclusive of chronic back pain and other musculoskeletal issues are arising in Taiwan which has made it imperative for them to rely on medication which is also estimated to improve the market demand for pain management drugs.

Taiwan Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. TAIWAN PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. TAIWAN PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. TAIWAN PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Novartis Pharmaceuticals Corporation (Novartis AG)

9.2. Pfizer Inc.

9.3. GlaxoSmithKline plc

9.4. Sanofi S.A

9.5. Viatris Inc.

9.6. Abbott Laboratories

9.7. Lumosa Therapeutics Co., Ltd.

9.8. Shionogi Inc. 

10. APPENDIX

10.1. Currency 

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key benefits for the stakeholders

10.5. Research Methodology 

10.6. Abbreviations 

Novartis Pharmaceuticals Corporation (Novartis AG)

Pfizer Inc.

GlaxoSmithKline plc

Sanofi S.A

Viatris Inc.

Abbott Laboratories

Lumosa Therapeutics Co., Ltd.